|Budget Amount *help
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2012: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
There is a distinct group of molecules within classical extracellular matrix proteins (ECM). These molecules should be called as matricellular proteins and we demonstrated that these proteins are involved in the pathogenesis of various intractable inflammatory disorders including rheumatoid arthritis and multiple sclerosis. Osteopontin (OPN) and tenascin-C (TN-C) are two examples and share common receptor, alpha9beta1 integrin and transducer intracellular signaling via this integrin receptor. Importantly, we found that OPN, TN-C and alpha9beta1 integrin are therapeutic targets in various inflammatory diseases and blocking monoclonal antibodies against OPN, TN-C and alpha9beta1 integrin can be future therapeutic antibody drugs.